melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
BRAF inhibitor resistance mediated by the AKT pathway in an oncogenic BRAF mouse melanoma model.
|
25624498 |
2015 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Melanoma specific killing was in the order; ZnO > B4C ≥ Cu > MgO > Co3O4 > Fe2O3 > NiO, ZnO-NP inhibiting B16F10 and A375 cells as well as ERK enzyme (>90%) and several other cancer-associated kinases (AKT, CREB, p70S6K).
|
29377653 |
2017 |
melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Prognostic significance of cyclooxygenase 2 and phosphorylated Akt1 overexpression in primary nonmetastatic and metastatic cutaneous melanomas.
|
28604419 |
2017 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
These results indicate that tumor cell susceptibility to a GSI, whether alone or in combination with chemotherapy, are reliant upon reducing AKT phosphorylation and hence GSI in combination with chemotherapy may be useful as a new therapeutic approach in treating PTEN-wild-type melanoma.
|
23564767 |
2013 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
PYCR1 promoted tumor progression through the AKT pathway in human MM in vitro.
|
30568501 |
2018 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
This review discusses the role MAPK and Phosphatidylinositol-3-kinase-protein kinase B-mammalian target of rapamycin (PI3K-AKT-mTOR) pathways play in the mechanism of resistance of melanomas.
|
28708099 |
2017 |
melanoma
|
0.500 |
GeneticVariation
|
disease |
BEFREE |
Dual MEK/AKT inhibition with trametinib and GSK2141795 does not yield clinical benefit in metastatic NRAS-mutant and wild-type melanoma.
|
28921907 |
2018 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Our data uncover an unsuspected role of HH-GLI signaling in melanocytes and melanomas, demonstrate a role for this pathway in RAS-induced tumors, suggest a general integration of the RAS/AKT and HH-GLI pathways, and open a therapeutic approach for human melanomas.
|
17392427 |
2007 |
melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Identification of mutations in the gene encoding the serine/threonine-protein kinase, BRAF, and constitutive activation of the mitogen-activated protein kinase (MAPK) pathway in around 50% of malignant melanomas have led to the development and regulatory approval of targeted pathway inhibitor drugs.
|
29100459 |
2017 |
melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In parallel, we assessed several human melanoma biopsy samples and found again that AKT2 was the predominantly activated AKT in these human melanoma biopsies.
|
19843246 |
2010 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In conclusion, Rictor plays an important role in melanoma VM via the Rictor-AKT-MMP-2/9 signalling pathway.
|
28699701 |
2017 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Recent evidence supports miRNA dysregulation in melanoma impacting several well-known pathways such as the PI3K/AKT or RAS/MAPK pathways, but also underexplored cellular processes like protein glycosylation and immune modulation.
|
22693259 |
2012 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Immune checkpoint and serine/threonine-protein kinase inhibitors have become a standard of care for advanced cutaneous melanoma, but dacarbazine-based chemotherapies are occasionally used.
|
30396963 |
2018 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
We propose that cotreatment increased ROS-induced cell cycle arrest and cellular apoptosis and inhibits melanoma growth by regulating the AKT-Nrf2 pathway in A375 cells which offers a possible therapeutic intervention strategy for the treatment of human melanoma.
|
29670684 |
2018 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Effects of AKT inhibitor therapy in response and resistance to BRAF inhibition in melanoma.
|
24735930 |
2014 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
This report shows that combining the AKT inhibitors (AZD5363 or MK1775) with the WEE1 inhibitor, AZD5363, can synergistically kill cultured melanoma cells and decrease melanoma tumor growth by greater than 90%.
|
28705772 |
2017 |
melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Our results indicated that AKT1 with a higher expression in melanoma showed enriched binding sites in the negative regulation of response to external stimulus, which enables cells to adapt to changes in external stimulation for survival.
|
27573172 |
2016 |
melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
In this review, we discuss the RAS-RAF-MAP kinase and the RAS-PI3K-AKT pathway in detail, as up to 80% of cutaneous melanomas exhibit a BRAF mutation.
|
17492934 |
2007 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In addition, functional experiments have demonstrated important roles for the PI3K-AKT pathway in both melanoma initiation and therapeutic resistance.
|
22453015 |
2012 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The findings add to evidence supporting a significant role for PTEN loss and the PI3K-AKT pathway in melanoma.
|
25165098 |
2014 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Clinical trials with PI3K-AKT-mTOR pathway inhibitors may be beneficial for melanoma patients with specific mTOR mutations.
|
26490311 |
2016 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
In summary, epigenetic PTEN silencing seems to be a relevant mechanism of inactivating this tumor suppressor gene in melanoma that may promote melanoma development by derepression of the AKT pathway.
|
16818626 |
2006 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
The epithelial-mesenchymal transition (EMT) regulatory factor SLUG (SNAI2) is a downstream target of SPARC and AKT in promoting melanoma cell invasion.
|
22911700 |
2012 |
melanoma
|
0.500 |
Biomarker
|
disease |
BEFREE |
Identification of WEE1 as a target to make AKT inhibition more effective in melanoma.
|
28853983 |
2018 |
melanoma
|
0.500 |
AlteredExpression
|
disease |
BEFREE |
Constitutive activation of Akt/protein kinase B in melanoma leads to up-regulation of nuclear factor-kappaB and tumor progression.
|
12499277 |
2002 |